98%
921
2 minutes
20
Introduction: Ventricular septal defect (VSD) is a common congenital heart disease (CHD), accounting for 20-30% of all CHD cases. While surgical closure has been the gold standard for treatment, transcatheter closure has emerged as a less invasive alternative, particularly for perimembranous VSDs. This study aimed to evaluate the early and mid-term outcomes of transcatheter closure using a double-disc occluder device in a single-center Vietnamese cohort.
Method: A prospective descriptive study was conducted at Hanoi Heart Hospital, Vietnam. A total of 81 patients aged ≥1 year or weighing ≥8 kg, with perimembranous VSDs and left-to-right shunting confirmed by Doppler echocardiography, underwent transcatheter closure. Procedural success, complications, and follow-up outcomes were assessed at 1, 3, 12, and 18 months post-procedure. Data were analyzed using SPSS 20.0.
Results: The procedure achieved a success rate of 96.4%, with three failures due to large defects near the aortic valve causing significant aortic regurgitation or residual shunting. No mortality or severe complications such as device embolization or complete atrioventricular block were observed. Minor complications included transient arrhythmias (6.2%), femoral hematoma (8.6%), and mild allergic reactions to contrast agents (9.9%). At 18 months follow-up, residual shunting was minimal in 1.2% of patients, and no cases required surgical intervention.
Discussion: Transcatheter closure of perimembranous VSD using a double-disc occluder device is a feasible, safe, and effective alternative to surgery with high success rates and low complication rates. This approach offers a promising solution for select patients, especially in resource-limited settings. Further multicenter studies are recommended to validate these findings and assess long-term outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985846 | PMC |
http://dx.doi.org/10.3389/fcvm.2025.1540595 | DOI Listing |
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
Trop Doct
September 2025
Professor, Department of Neonatology, Graphic Era Institute of Medical Sciences, Dehradun, Uttarakhand, India.
World J Methodol
December 2025
Department of Cardiology, University of Miami-Miller School of Medicine, Miami, FL 33136, United States.
Background: The Food and Drug Administration has approved percutaneous atrial septal defect (ASD) and patent foramen ovale (PFO) closure devices for hemodynamically significant interatrial shunts, paradoxical emboli including stroke, and decompression sickness. We aimed to study the trends in utilization and reimbursements of transcatheter ASD/PFO closure devices.
Aim: To analyze trends in utilization and Medicare reimbursements for transcatheter ASD/PFO closure procedures from 2013 to 2022.
JACC Cardiovasc Interv
August 2025
Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France; UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, France; Hanoï Medical University, Vietnam. Electronic address:
Background: Acquired von Willebrand factor (vWF) deficiency is a key contributor to bleeding after transcatheter aortic valve replacement (TAVR).
Objective: To evaluate whether assessing primary hemostatic disorder using closure time of adenosine diphosphate (CT-ADP), a marker of vWF dysfunction, enhances bleeding risk stratification in TAVR patients at high bleeding risk (HBR).
Methods: We analyzed 884 patients from a prospective TAVR registry.
Eur Heart J Imaging Methods Pract
January 2025
Division of Cardiology, Department of Internal Medicine, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
Aims: Paradoxical embolism from a patent foramen ovale (PFO) can cause cryptogenic stroke. Agitated saline contrast transthoracic echocardiography (ASC-TTE), with the Valsalva manoeuvre (VM), is crucial for diagnosing PFO. However, the VM is associated with false-negative outcomes.
View Article and Find Full Text PDF